These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up. Greenberg RN, Feinberg J, Goodrich J, Pilson RS, Siemon-Hryczyk P. Antivir Ther; 2003 Feb 24; 8(1):37-42. PubMed ID: 12713062 [Abstract] [Full Text] [Related]
9. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy. Moore DM, Hogg RS, Yip B, Wood E, Harris M, Montaner JS. HIV Med; 2006 Jul 24; 7(5):311-6. PubMed ID: 16945076 [Abstract] [Full Text] [Related]
10. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study. Mallolas J, Blanco J, Labarga P, Vergara A, Ocampo A, Sarasa M, Arnedo M, López-Púa Y, García J, Juega J, Guelar A, Terrón A, Dalmau D, García I, Zárraga M, Martínez E, Carné X, Pumarola T, Escayola R, Gatell J. HIV Med; 2007 May 24; 8(4):226-33. PubMed ID: 17461850 [Abstract] [Full Text] [Related]
13. Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy. Walter H, Schmidt B, Rascu A, Helm M, Moschik B, Paatz C, Kurowski M, Korn K, Uberla K, Harrer T. Antivir Ther; 2000 Dec 24; 5(4):249-56. PubMed ID: 11142619 [Abstract] [Full Text] [Related]
14. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, LeBraz M, Jupimai T, Ubolyam S, Schutz M, Hirschel B, Staccato Thailand Study Group. Antivir Ther; 2008 Dec 24; 13(3):375-80. PubMed ID: 18572750 [Abstract] [Full Text] [Related]
15. Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection. Hoffmann F, Notheis G, Wintergerst U, Eberle J, Gürtler L, Belohradsky BH. Pediatr Infect Dis J; 2000 Jan 24; 19(1):47-51. PubMed ID: 10643850 [Abstract] [Full Text] [Related]
17. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E, SWAN Study Group. Clin Infect Dis; 2007 Jun 01; 44(11):1484-92. PubMed ID: 17479947 [Abstract] [Full Text] [Related]